The Endgame on Oncology Endpoints
Executive Summary
The annual ASCO meeting, held in Chicago this year, provided a forum for investigators to discuss the merits of continued use of progression-free survival as an endpoint in oncology clinical trials. Phase III data from Roche/Genentech's Avastin in metastatic breast cancer sparked debate.
You may also be interested in...
Provenge Fails To Meet Interim Study Endpoint, But Dendreon Will Press On
Dendreon will have to wait until mid-2009 at the earliest for final study results of its prostate cancer vaccine Provenge, after it failed to meet the primary endpoint in an interim look at the data
Cancer Vaccine R&D Makes Strides With Better Endpoints, Patient Selection
As cancer vaccine and immunotherapy developers try to get past the difficulties of recent years, they are looking to improve their chances for success by identifying the correct cancer types and settings to best respond to a specific vaccine and then choosing more meaningful endpoints for clinical trials.
Cancer Vaccine R&D Makes Strides With Better Endpoints, Patient Selection
As cancer vaccine and immunotherapy developers try to get past the difficulties of recent years, they are looking to improve their chances for success by identifying the correct cancer types and settings to best respond to a specific vaccine and then choosing more meaningful endpoints for clinical trials